Adaptimmune Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.09.24	Biotech Stocks Facing FDA Decision In September 2024 (RTTNews)
04.08.24	Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid (RTTNews)
29.07.24	Biotech Stocks Facing FDA Decision In August 2024 (RTTNews)
11.04.23	SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ROCC, KBAL, ADAP, TCRR (PR Newswire)
06.04.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RADI, ADAP, TCRR (PR Newswire)
28.03.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROCC, RADI, ADAP, TCRR (PR Newswire)
23.03.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSEY, ADAP, TCRR (PR Newswire)
16.03.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JNCE, ADAP, TCRR (PR Newswire)
07.03.23	INVESTIGATION ALERT: Halper Sadeh LLC Investigates RADI, ADAP, TCRR, ROCC (PR Newswire)
06.03.23	Adaptimmune To Combine With TCR² In All-stock Deal - Quick Facts (RTTNews)
10.05.22	ADCT Awaits Cami Trial Data, CSTL Boosts Revenue Outlook, ANNX To Report HD Trial Data In Q2 (RTTNews)
07.09.21	Adaptimmune Inks JV With Genentech To Develop Allogeneic T-cell Therapies - Quick Facts (RTTNews)
05.09.21	Adaptimmune : Phase 1 Trial Data On Liver Cancer Show Significant Antitumor Activity (RTTNews)
29.05.20	Adaptimmune : Phase 1 Trial On ADP-A2M4 Shows Durability And Responses In Synovial Sarcoma (RTTNews)
14.01.20	Astellas, Adaptimmune To Co-Develop And Co-Commercialize T-cell Therapies (RTTNews)
25.10.19	Healthcare Stocks On The Move (EW, NVO, BBI…) (RTTNews)
23.10.18	ADAP Down 46% This Month, CLVS Abuzz, ADRO Awaits Data In Nov. (RTTNews)
22.03.18	GERN Turning Heads, ARQL To Present Data In Apr., Mark Your Calendar For PTN (RTTNews)
16.03.18	DXR On Fire, IONS Ups Stake In AKCA, HAIR Grows, FLKS To Report Data This Month (RTTNews)
15.03.18	Adaptimmune Announces Responses In Second Solid Tumor Indication (RTTNews)
08.01.18	Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company (GlobeNewswire)
08.12.17	In The Spotlight: Adaptimmune Therapeutics (RTTNews)
06.11.17	Adaptimmune marks Official Opening of U.K. Headquarters (GlobeNewswire)
08.09.17	NLNK Rallies On Indoximod Data, VRNA Breathes Easy, ALNY Jolted (RTTNews)
07.09.17	Adaptimmune: GSK Exercises Option Over NY-ESO SPEAR T-Cell Therapy Program (RTTNews)
07.09.17	GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO (GlobeNewswire)
01.09.17	IPXL Reveals Oriental Stakeholder, LENS Has A Vision, STDY Is Very Shaky (RTTNews)
29.08.17	So Long To KITE; JUNO, CLLS, MBIO, BLCM Are Sympathy Plays; PGNX Catches Eye (RTTNews)
13.07.17	Gainers & Losers Of July 12: CALA, TRVN, GEMP, ALDR, INSY... (RTTNews)
07.04.17	Gainers & Losers Of Apr.6: HTGM, AKTX, FGEN, ARLZ, ADAP... (RTTNews)
05.12.16	Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study (GlobeNewswire)
10.11.16	Adaptimmune Reports Third Quarter 2016 Financial Results (GlobeNewswire)
27.10.16	Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma (GlobeNewswire)
26.09.16	MD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple Cancers (GlobeNewswire)
08.08.16	Adaptimmune Reports Second Quarter 2016 Financial Results (GlobeNewswire)
03.08.16	Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR® T-cell Therapy in Myxoid Round Cell Liposarcoma (GlobeNewswire)
28.07.16	Adaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR® T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma (GlobeNewswire)
26.07.16	Adaptimmune Receives Orphan Drug Designation in the European Union for its NY-ESO SPEAR® T-cell Therapy for Treatment of Soft Tissue Sarcoma (GlobeNewswire)
21.06.16	Adaptimmune Announces Commercial Development and Supply Agreement for Thermo Fisher Scientific's Dynabeads(TM) CD3/CD28 Cell Therapy System (GlobeNewswire)
20.06.16	Adaptimmune Receives Positive Opinion for Orphan Drug Designation in the European Union for SPEAR(TM) T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma (GlobeNewswire)
12.05.16	Adaptimmune Reports First Quarter 2016 Financial Results (GlobeNewswire)
07.04.16	Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting AFP in Liver Cancer (GlobeNewswire)
17.03.16	Adaptimmune Reports Financial Results for the Six-Month Period ended December 31, 2015 (GlobeNewswire)
09.02.16	U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune's Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma (GlobeNewswire)
02.02.16	Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration (GlobeNewswire)
22.01.16	Adaptimmune Announces New Additions to Manufacturing Senior Management (GlobeNewswire)
17.12.15	Adaptimmune Announces Initiation of Study to Evaluate its New Affinity Enhanced T-Cell Therapy Targeting MAGE-A10 in Patients With NSCLC, the Most Common Form of Lung Cancer (GlobeNewswire)
01.12.15	Adaptimmune and Universal Cells Announce Collaboration to Develop Allogeneic T-Cell Therapies (GlobeNewswire)
24.11.15	Adaptimmune Initiates Phase I / II Trial Evaluating Its Affinity Enhanced T-Cell Therapy Targeting NY-ESO-1 in Patients With the Most Common Type of Lung Cancer (GlobeNewswire)
13.11.15	Adaptimmune Reports First Quarter Financial Results for Fiscal Year 2015-16 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Adaptimmune Therapeutics PLC (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten